Life Science Seminar<br />Proinvestor<br />5. October 2011<br /> <br />Martin Welschof<br />Managing Director, Affitech A/...
Disclaimer<br />Forward Looking Statements<br />.<br />Affitech A/S is a public company listed on NASDAQ OMX Copenhagen. R...
Company snapshot <br />Affitech A/S, October, 2011<br /><ul><li>Promising lead drug candidates:
AT001/r84:A human selective anti-VEGF antibody with a new mode of action
AT008/CCR4: The first CBASTM antibody targeting a GPCR - advancing to candidate selection
Broad and growing pipeline of GPCR drug candidates
Powerful antibody discovery engine:
Unique proprietary technology platform, placing  Affitech at the forefront of antibody innovation
Partnerships:
Strong strategic partnerships for research, co-development and marketing</li></li></ul><li>Solid intellectual property pla...
Pending in USA, Australia, Canada, Israel, India, China, Brazil, Norway, Croatia, Serbia</li></ul>AT001/r84 patent<br /><u...
Powerfultechnology drives discoveryengine<br />Platform withhighcapacity to isolate multiple fully human antibody <br />ca...
AT001/r84 – potential for greater safety<br />AT001/r84 antibody is a proprietary  antibody with anovel  mechanism of acti...
Binds VEGF selectively, inhibiting binding to VEGFR2 only and not VEGFR1
Preclinical data shows efficacy at least equal to Avastin® (bevacizumab)
Shows limited induction of side effects</li></ul>Large market opportunity for AT001/r84 in<br />emerging markets :<br /><u...
Low penetration of Avastin® in Russia/CIS
An anti-VEGF antibody has top priority on Russian short list of innovative drugs to be marketed by 2015</li></ul>Affitech ...
AT001/r84 – more specific inhibition (VEGF)<br />AT001/r84<br />More selective for anti-angiogenesis<br />Avastin®<br />VE...
AT001/r84 progressing well<br /><ul><li>First GMP manufacturing (through AVID) completed
Upcoming SlideShare
Loading in...5
×

Affitech

819

Published on

Published in: Economy & Finance, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
819
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Affitech

  1. 1. Life Science Seminar<br />Proinvestor<br />5. October 2011<br /> <br />Martin Welschof<br />Managing Director, Affitech A/S<br />Affitech A/S, October, 2011<br />
  2. 2. Disclaimer<br />Forward Looking Statements<br />.<br />Affitech A/S is a public company listed on NASDAQ OMX Copenhagen. Recipients of this presentation are advised that this written presentation and any verbal comments to it provided by Executive Management contain forward looking statements, including without limitation those regarding Affitech’s financial position, business strategy, news flow, plans and objectives for future operations, including development plans and objectives relating to our products. Such forward looking statements are based upon assumptions of future events which may not prove to be accurate and involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by such forward looking statements. In addition, the forward looking statements in this document speak only as of the date of this presentation<br />
  3. 3. Company snapshot <br />Affitech A/S, October, 2011<br /><ul><li>Promising lead drug candidates:
  4. 4. AT001/r84:A human selective anti-VEGF antibody with a new mode of action
  5. 5. AT008/CCR4: The first CBASTM antibody targeting a GPCR - advancing to candidate selection
  6. 6. Broad and growing pipeline of GPCR drug candidates
  7. 7. Powerful antibody discovery engine:
  8. 8. Unique proprietary technology platform, placing Affitech at the forefront of antibody innovation
  9. 9. Partnerships:
  10. 10. Strong strategic partnerships for research, co-development and marketing</li></li></ul><li>Solid intellectual property platform <br />Affitech A/S, October, 2011<br />The Breitling patent<br /><ul><li>Worldwide exclusive rights covering certain aspects of phagemid display of human antibodies, acquired from the German Cancer Centre in Heidelberg</li></ul>Cell Based Antibody Selection – CBASTM patent<br /><ul><li>Granted patent in EU, Russia, Japan, New Zealand, South Africa, Singapore
  11. 11. Pending in USA, Australia, Canada, Israel, India, China, Brazil, Norway, Croatia, Serbia</li></ul>AT001/r84 patent<br /><ul><li>Patent pending in EU, EAPO, Ukraine, Japan, USA, China, India, South Korea, Singapore, South Africa, Israel, Brazil, Columbia, Mexico, Canada, Australia, New Zealand</li></ul>CCR4andCXCR4 patents <br /><ul><li>Applications filed (pre-PCT or early PCT phase) in the UK and USA</li></li></ul><li>Exciting antibody pipeline<br />Target<br />Drug candidate<br />Diseasearea<br />Partner<br />Status<br />Anti-VEGF <br />(VascularEndothelialGrowth Factor)<br />AT001/r84<br />Cancer<br />IBC Generium (Russia/CIS)<br />Unpartnered in otherterritories<br />CTA filed, Phase I trialsscheduled in 2011<br />CCR4, a GPCR<br />(G-protein coupled receptor)<br />AT008/CCR4<br />Cancer, autoimmune diseases<br />IBC Generium (Russia/CIS)<br />Unpartnered in otherterritories<br />Preclinicaltesting<br />Candidateselected<br />Beta2glycoprotein1 Phosphatidylserine<br />AT004<br />Cancer, infectiousdiseases<br />Peregrine Pharmaceuticals<br />Not disclosed<br />Phosphatidylserine<br />AT005<br />Cancer, infectiousdiseases<br />Peregrine Pharmaceuticals<br />Not disclosed<br />Angiopoietin-2<br />AT006<br />Cancer<br />Roche<br />In development <br />CXCR4, a GPCR<br />AT009<br />Cancer<br />Unpartnered<br />Research<br />Severalother GPCR programs<br />Cancer, inflammation<br />Unpartnered<br />Research<br />
  12. 12. Powerfultechnology drives discoveryengine<br />Platform withhighcapacity to isolate multiple fully human antibody <br />candidates to targetswithchallengingspecificities<br />CBASTM – cellbased antibody selection<br />
  13. 13. AT001/r84 – potential for greater safety<br />AT001/r84 antibody is a proprietary antibody with anovel mechanism of action:<br /><ul><li>A fully human antibody
  14. 14. Binds VEGF selectively, inhibiting binding to VEGFR2 only and not VEGFR1
  15. 15. Preclinical data shows efficacy at least equal to Avastin® (bevacizumab)
  16. 16. Shows limited induction of side effects</li></ul>Large market opportunity for AT001/r84 in<br />emerging markets :<br /><ul><li>Potential to be a better “Avastin®”, which had sales of ~USD 5.9bn in 2009
  17. 17. Low penetration of Avastin® in Russia/CIS
  18. 18. An anti-VEGF antibody has top priority on Russian short list of innovative drugs to be marketed by 2015</li></ul>Affitech A/S, October, 2011<br />Scheduled to enter phase I clinical trial in Russia in 2011 <br />
  19. 19. AT001/r84 – more specific inhibition (VEGF)<br />AT001/r84<br />More selective for anti-angiogenesis<br />Avastin®<br />VEGFR2<br />VEGFR1<br />VEGFR2<br />VEGFR1<br />the dominant ‘angiogenic’ receptor<br />Affitech A/S, October, 2011<br />
  20. 20. AT001/r84 progressing well<br /><ul><li>First GMP manufacturing (through AVID) completed
  21. 21. Preparing Clinical Trial Application for submission
  22. 22. Collaboration agreement with Dr. Rolf Brekken(University of Texas Southwestern), for further mechanistic studies in disease models</li></li></ul><li>GPCRs - major opportunity for antibody approach<br />Affitech A/S, October, 2011<br /><ul><li>G-protein coupled receptors (GPCRs) can be used where inhibition by small molecule chemistry has proven difficult
  23. 23. Multi-ligandGPCRs can be targeted for antibody therapy
  24. 24. GPCRs - the largest known protein family at >2% of the entire genome
  25. 25. Involved in a wide range of disorders and biological functions
  26. 26. ~20% of current drugs target GPCRs but only a fraction of the cell surface receptors</li></li></ul><li>AT008/CCR4 in progress<br />A potential development candidate has been identified <br /><ul><li>Clinically validated target:
  27. 27. NDA filed in Japan for anti-CCR4 antibodyKW-0761 to treat Adult T-cell Leukemia-Lymphoma (ATL) (Kyowa Hakko Kirin, partnered with Amgen)
  28. 28. Preliminary proof of concept
  29. 29. A xenograph model successfully completed
  30. 30. Development of an AT008/CCR4 manufacturing cell line initiated
  31. 31. Six other chemokine receptor programs are being profiled in in vitro and in vivo models
  32. 32. Collaboration agreement with Professor Frances Balkwill, Cancer Research Technology Ltd. UK for further validation of the CCR4 target</li></li></ul><li>Antibodies to GPCRs – potential indications<br />Affitech A/S, October, 2011<br /><ul><li>Primary tumors in both hematological cancers and solid tumors
  33. 33. Metastatic lesions
  34. 34. Regulatory T cells (in stroma and circulation)</li></li></ul><li>Affitech’s bispecific antibody program: BIMS<br />Affitech A/S, October, 2011<br /><ul><li>BIMS – “Bispecific IgG-like Molecule of enhanced Selectivity”
  35. 35. Next generation dual specificity/functionality antibody-like molecules
  36. 36. BIMS is a molecule which has the size of a normal IgG antibody. Since it is tetravalent is has a longer half-life in circulation</li></li></ul><li>Valuable strategic partnerships<br />AT001/r84 and AT008. Fast track to market. Financing of clinical trials in Russia. Marketing in Russia and the other CIS countries. Affitechretainsworldwiderights. Opportunity to leverage into other emerging markets<br />Collaboration on AT004 and AT005, in cancer and infectious diseases<br />AT006 / Ang-2 program. Roche is using Affitech’s Ang-2 antibody in a bi-specific format with Avastin®<br />GMP Manufacturing for AT001/r84<br />IBC Generium<br />Exploring further development partnerships in BRIC or other regions of the world<br />
  37. 37. Excellent research collaborations<br />Affitech A/S, October, 2011<br /><ul><li>Research collaboration with Professor Frances Balkwill, Cancer Research Technology Ltd. UK for further validation of CCR4 target
  38. 38. Research collaborationwith Dr. Rolf Brekken, University of Texas Southwestern Medical Center, Dallas, USA for furthermechanistic studies of AT001/r84 in disease models</li></li></ul><li>Priorities and timelines - key milestones 2011 <br />Affitech A/S, October, 2011<br />
  39. 39. Listing details<br />Affitech A/S, October, 2011<br />Listed on Nasdaq OMX Copenhagen (AFFI)<br />Ownership: <br /><ul><li>TransNova Inv. Ltd.: 40%
  40. 40. Krosalter Enterprises Ltd. 13,3%,
  41. 41. Norwegian PE and institutions: ~30%
  42. 42. Danish private investors: ~17%</li></li></ul><li>A multicultural organization<br />Affitech A/S, October, 2011<br />30+ people, 27 scientists,  10 of which are PhDs <br />Experienced international executive management team:<br /><ul><li>Managing Director Martin Welschof, German, one of Affitech’s founders
  43. 43. CFO Stig Jarle Pettersen, Norwegian state authorized public accountant
  44. 44. CSO Alexander Duncan, British, a leading antibody research scientist and business leader</li></ul>Facilities in Copenhagen Bio Science Park , Denmark and in the Research Park in Oslo, Norway<br />
  45. 45. Contactdetails<br />Affitech A/S, October, 2011<br />Affitech A/S<br /> Copenhagen, Denmark<br />c/o COBIS<br />Ole Maaløes Vej 3<br />DK- 2200 Kbh. N<br />Denmark<br />Telephone: +45 39 17 82 59<br />Email: IR@affitech.comf <br />Affitech Research, Oslo, Norway<br />Gaustadalléen 21<br />N-0349 Oslo<br />Norway<br />Telephone: +47 22 95 87 58<br />Fax: +47 22 95 83 58<br />Email: INFO@affitech.com<br />WWW.affitech.com<br />
  46. 46. Affitech A/S addresses unmet medical needs in cancer, including hematological and solid tumors, <br />and in serious inflammatory conditions<br />Thank you for your attention<br />
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×